Cargando…
Cmpd10357 to treat B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is the most common type of cancer found in children. Although the overall survival rates are now >80%, 15%–20% of pediatric patients relapse, with survival rates subsequently dropping to 5%–10%. Cmpd10357, 3-amino-5-arylamino-6-chloro-N- (diaminomethyle...
Autores principales: | Lee, Alex Q., Konishi, Hiroaki, Helmke, Elizabeth, Ijiri, Masami, Lerot, Jan Michael A., Hicks, Emma, Chien, Jeremy R., Gorin, Fredric A., Satake, Noriko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033359/ https://www.ncbi.nlm.nih.gov/pubmed/36621746 http://dx.doi.org/10.1016/j.exphem.2022.12.005 |
Ejemplares similares
-
A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile
por: Lee, Alex Q., et al.
Publicado: (2022) -
CMPD: cancer mutant proteome database
por: Huang, Po-Jung, et al.
Publicado: (2014) -
Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
por: Gurgis, FMS, et al.
Publicado: (2015) -
Assessment of Ultrasonic Stress on Survival and β-Glucosidase Activity of Encapsulated Lactiplantibacillus plantarum BCRC 10357 in Fermentation of Black Soymilk
por: Tseng, Hung-Chih, et al.
Publicado: (2022) -
MK2a inhibitor CMPD1 abrogates chikungunya virus infection by modulating actin remodeling pathway
por: Mamidi, Prabhudutta, et al.
Publicado: (2021)